Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at

Lexicon sotagliflozin shows consistent results across blood pressure levels

Mon, 31 Aug 2026 08:32:12 -0400

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial, showing that sotagliflozin's effects were consistent across baseline systolic blood pressure levels in patients recently hospitalized for worsening heart failure.

The findings were presented at ESC Congress 2026 in Munich, Germany, and simultaneously published in JACC: Heart Failure.

The analysis, based on data from 1,222 patients with type 2 diabetes, showed that sotagliflozin reduced cardiovascular death and heart failure-related events regardless of baseline systolic blood pressure. Among patients with a baseline systolic blood pressure below 110 mmHg (n=201), those receiving sotagliflozin experienced a reduction in

Lexicon sotagliflozin shows consistent results across blood pressure levels

Mon, 31 Aug 2026 08:32:12 -0400

The findings were presented at ESC Congress 2026 in Munich, Germany, and simultaneously published in JACC: Heart Failure.

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Mon, 31 Aug 2026 08:30:00 -0400

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

THE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure.

The data, which were presented yesterday at ESC Congress 2026 in Munich, Germany and simultaneously published in JACC: Heart Failure¹, demonstrated that the results of sotagliflozin treatment

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Mon, 31 Aug 2026 08:30:00 -0400

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

The data, which were presented yesterday at ESC Congress 2026 in Munich, Germany and simultaneously published in JACC: Heart Failure¹, demonstrated that the results of sotagliflozin treatment

Lexicon earns third $10M milestone from Novo Nordisk for LX9851

Mon, 24 Aug 2026 08:30:17 -0400

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S after achieving a patient dosing milestone in the Phase 1 clinical development program for LX9851, an oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders.

With this payment, Lexicon has now received $75 million of a potential $1 billion in upfront, development, regulatory, and commercial milestone payments available under its collaboration with Novo Nordisk. Lexicon is also entitled to tiered royalties on future net sales of LX9851.

Novo Nordisk obtained an exclusive worldwide license to develop, manufacture,

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Mon, 24 Aug 2026 08:30:00 -0400

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Mon, 24 Aug 2026 08:30:00 -0400

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

Form EFFECT LEXICON PHARMACEUTICALS,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934368.html

Form EFFECT LEXICON PHARMACEUTICALS,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934368.html

Form S-3 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885439.html

Form S-3 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885439.html

Form S-8 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884810.html

Form S-8 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884810.html

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883723.html

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883723.html

Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881239.html

Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881239.html

Lexicon Pharma (LXRX) Misses Q2 EPS by 2c

Thu, 06 Aug 2026 07:50:09 -0400

Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06

Thu, 06 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26878878.html

Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06

Thu, 06 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26878878.html

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Thu, 06 Aug 2026 07:30:00 -0400

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027

NDA resubmission activities for ZYNQUISTA^® in type 1 diabetes nearing completion

Phase 1 clinical development of LX9851 ongoing by Novo Nordisk

Conference call and webcast at 8:30 am ET

THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments.

“Lexicon continued to make strong progress during the

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Thu, 06 Aug 2026 07:30:00 -0400

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027

NDA resubmission activities for ZYNQUISTA^® in type 1 diabetes nearing completion

Phase 1 clinical development of LX9851 ongoing by Novo Nordisk

Conference call and webcast at 8:30 am ET

“Lexicon continued to make strong progress during the

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 08:30:00 -0400

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin

StreetInsider.com News Articles

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon sotagliflozin shows consistent results across blood pressure levels

Lexicon sotagliflozin shows consistent results across blood pressure levels

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon earns third $10M milestone from Novo Nordisk for LX9851

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Form EFFECT LEXICON PHARMACEUTICALS,

Form EFFECT LEXICON PHARMACEUTICALS,

Form S-3 LEXICON PHARMACEUTICALS,

Form S-3 LEXICON PHARMACEUTICALS,

Form S-8 LEXICON PHARMACEUTICALS,

Form S-8 LEXICON PHARMACEUTICALS,

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC

Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC

Lexicon Pharma (LXRX) Misses Q2 EPS by 2c

Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06

Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026